July 2009
- Sorafenib fourth-line treatment in imatinib-, sunitinib-, and nilotinib-resistant metastatic GIST
- In vitro activity of sorafenib against imatinib- and sunitinib-resistant kinase mutations
- Phase I evaluation of SF1126, a vascular targeted PI3K inhibitor, administered twice weekly IV
- Evaluation of the presence of IGF1R over expression in wildtype and kinase mutant GI stromal tumors
- Masatinib mesylate in imatinib-naive locally advanced or metastatic gastrointestinal stromal tumor
- Analysis of an observational registry of gastrointestinal stromal tumor (GIST) patients
- Myelodysplastic syndromes developing after imatinib therapy for GIST
- Gastrointestinal stromal tumor associated with other primaries: A study of 154 patients
July 2009
- Sorafenib fourth-line treatment in imatinib-, sunitinib-, and nilotinib-resistant metastatic GIST by Jim Hughes Dr. Peter Reichardt presented a retrospective study wherein sorafenib showed significant clinical activity in resistant metastatic GIST patients.
- In vitro activity of sorafenib against imatinib- and sunitinib-resistant kinase mutations by Jim Hughes Jonathan Fletcher presented results showing that sorafenib has superior in vitro potency compared with imatinib or sunitinib against a panel of GIST-relevant mutant kinase cell lines and models.
- Phase I evaluation of SF1126, a vascular targeted PI3K inhibitor, administered twice weekly IV by Jim Hughes Four GIST patients have entered this Phase 1 trial of PI3K inhibitor SF1126.
-
Evaluation of the presence of IGF1R over expression in wildtype and kinase mutant GI stromal tumors
by Jim Hughes
Fifteen percent of adult patients and 90 percent of pediatric patients have wildtype GIST.
Corless presented data showing a wide degree of expression in IGF-1R levels in 114
patients with various GIST mutations including 51 wildtype cases. -
Masatinib mesylate in imatinib-naive locally advanced or metastatic gastrointestinal stromal tumor
by Jim Hughes
Thirty patients are reported in this Phase II trial analysis. Results indicate a favorable
comparison with imatinib as a first-line treatment for GIST. - Analysis of an observational registry of gastrointestinal stromal tumor (GIST) patients by Jim Hughes This poster reported the latest data from the GIST ReGISTry, an online database of GIST patient statistics maintained by a group of American and Canadian GIST specialists and supported by Novartis Pharmaceuticals.
- Myelodysplastic syndromes developing after imatinib therapy for GIST by Jim Hughes In a prospective study of 49 GIST patients, the authors conclude that during imatinib therapy some patients with GIST develop chromosomal abnormalities and that, although rare, these findings highlight the need for monitoring GIST patients treated with imatinib.
- Gastrointestinal stromal tumor associated with other primaries: A study of 154 patients by Jim Hughes In a retrospective study of GIST patients treated at MD Anderson Cancer Center from 1995 through 2007, 153 of 783 (20 percent) patients were identified as having a primary cancer in addition to GIST.